Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Wakeling

Showing results (71-80 of 88) with videos related to

Pageof 9
Sort By:
Cancer Research|October 18, 2002
ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapyAlan E Wakeling, Simon P Guy, Jim R Woodburn, et al.
Breast Cancer Research and Treatment|October 9, 2003
Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cellsIain R Hutcheson, Janice M Knowlden, Tracie-Ann Madden, et al.
Cancer Research|July 15, 1993
MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780N Brünner, T L Frandsen, C Holst-Hansen, et al.
European Journal of Cancer (Oxford, England : 1990)|March 1, 1996
Short-term effects of pure anti-oestrogen ICI 182780 treatment on oestrogen receptor, epidermal growth factor receptor and transforming growth factor-alpha protein expression in human breast cancerR A McClelland, J M Gee, A B Francis, et al.
Breast Cancer Research and Treatment|January 1, 1996
Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolinesA E Wakeling, A J Barker, D H Davies, et al.
Annals of the New York Academy of Sciences|April 30, 1996
Pure antiestrogens. The most important advance in the endocrine therapy of breast cancer since 1896R I Nicholson, J M Gee, S Bryant, et al.
The Prostate|May 7, 2002
Multiple responses to EGF receptor activation and their abrogation by a specific EGF receptor tyrosine kinase inhibitorMaureen E Harper, Lindy Goddard, Eve Glynne-Jones, et al.
Journal of the National Cancer Institute|May 17, 1995
Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancerC K Osborne, E B Coronado-Heinsohn, S G Hilsenbeck, et al.
Endocrinology|February 15, 2003
Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cellsJanice M Knowlden, Iain R Hutcheson, Helen E Jones, et al.
Endocrine-Related Cancer|December 23, 2004
Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cellsH E Jones, L Goddard, J M W Gee, et al.
Pageof 9

Showing results (71-80 of 88) with videos related to

Sort By:
Pageof 9
Cancer Research|October 18, 2002
ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapyAlan E Wakeling, Simon P Guy, Jim R Woodburn, et al.
Breast Cancer Research and Treatment|October 9, 2003
Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cellsIain R Hutcheson, Janice M Knowlden, Tracie-Ann Madden, et al.
Cancer Research|July 15, 1993
MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780N Brünner, T L Frandsen, C Holst-Hansen, et al.
European Journal of Cancer (Oxford, England : 1990)|March 1, 1996
Short-term effects of pure anti-oestrogen ICI 182780 treatment on oestrogen receptor, epidermal growth factor receptor and transforming growth factor-alpha protein expression in human breast cancerR A McClelland, J M Gee, A B Francis, et al.
Breast Cancer Research and Treatment|January 1, 1996
Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolinesA E Wakeling, A J Barker, D H Davies, et al.
Annals of the New York Academy of Sciences|April 30, 1996
Pure antiestrogens. The most important advance in the endocrine therapy of breast cancer since 1896R I Nicholson, J M Gee, S Bryant, et al.
The Prostate|May 7, 2002
Multiple responses to EGF receptor activation and their abrogation by a specific EGF receptor tyrosine kinase inhibitorMaureen E Harper, Lindy Goddard, Eve Glynne-Jones, et al.
Journal of the National Cancer Institute|May 17, 1995
Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancerC K Osborne, E B Coronado-Heinsohn, S G Hilsenbeck, et al.
Endocrinology|February 15, 2003
Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cellsJanice M Knowlden, Iain R Hutcheson, Helen E Jones, et al.
Endocrine-Related Cancer|December 23, 2004
Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cellsH E Jones, L Goddard, J M W Gee, et al.
Pageof 9